BRPI0516832A - uso para alfa-simpatomiméticos com uma estrutura de 2-imidazolina - Google Patents

uso para alfa-simpatomiméticos com uma estrutura de 2-imidazolina

Info

Publication number
BRPI0516832A
BRPI0516832A BRPI0516832-5A BRPI0516832A BRPI0516832A BR PI0516832 A BRPI0516832 A BR PI0516832A BR PI0516832 A BRPI0516832 A BR PI0516832A BR PI0516832 A BRPI0516832 A BR PI0516832A
Authority
BR
Brazil
Prior art keywords
sympathomimetics
alpha
imidazoline structure
imidazoline
sympathometics
Prior art date
Application number
BRPI0516832-5A
Other languages
English (en)
Inventor
Fritz Sacher
Marion Tschaikin
Stephan Koelsch
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35276675&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0516832(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BRPI0516832A publication Critical patent/BRPI0516832A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

USO PARA ALFA-SIMPATOMIMéTICOS COM UMA ESTRUTURA DE 2-IMIDAZOLINA. A presente refere-se ao uso de <244>-simpatomiméticos com estrutura de 2-imidazolina para a preparação de um medicamento para profilaxia e/ou tratamento de doenças virais.
BRPI0516832-5A 2004-10-05 2005-09-16 uso para alfa-simpatomiméticos com uma estrutura de 2-imidazolina BRPI0516832A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004049008A DE102004049008A1 (de) 2004-10-05 2004-10-05 Neue Verwendung für α-Sympathomimetika mit 2-Imidazolinstruktur
PCT/EP2005/010026 WO2006037452A1 (de) 2004-10-05 2005-09-16 NEUE VERWENDUNG FÜR α-SYMPATHOMIMETIKA MIT 2-IMIDAZOLINSTRUKTUR

Publications (1)

Publication Number Publication Date
BRPI0516832A true BRPI0516832A (pt) 2008-09-23

Family

ID=35276675

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0516832-5A BRPI0516832A (pt) 2004-10-05 2005-09-16 uso para alfa-simpatomiméticos com uma estrutura de 2-imidazolina

Country Status (20)

Country Link
US (1) US20080108685A1 (pt)
EP (1) EP1802302B1 (pt)
JP (1) JP5311825B2 (pt)
KR (1) KR20070059134A (pt)
CN (1) CN101022797B (pt)
AU (1) AU2005291603B2 (pt)
BR (1) BRPI0516832A (pt)
CA (1) CA2582984C (pt)
CY (1) CY1118581T1 (pt)
DE (1) DE102004049008A1 (pt)
DK (1) DK1802302T3 (pt)
ES (1) ES2612544T3 (pt)
HU (1) HUE031515T2 (pt)
LT (1) LT1802302T (pt)
MX (1) MX2007004040A (pt)
PL (1) PL1802302T3 (pt)
PT (1) PT1802302T (pt)
RU (1) RU2397764C2 (pt)
WO (1) WO2006037452A1 (pt)
ZA (1) ZA200703622B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004049008A1 (de) 2004-10-05 2006-04-06 Merck Patent Gmbh Neue Verwendung für α-Sympathomimetika mit 2-Imidazolinstruktur
US12343427B1 (en) * 2024-04-23 2025-07-01 Nivagen Pharmaceuticals, Inc. Stable intravenous diltiazem hydrochloride formulation and use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2137981T3 (es) 1991-11-19 2000-01-01 Univ Virginia Tratamiento combinado por agentes antimediaticos y antiviricos de resfriados comunes.
JPH06211659A (ja) * 1993-01-19 1994-08-02 Kowa Co 点鼻薬組成物
US5576437A (en) 1993-12-17 1996-11-19 The Procter & Gamble Company 7-(2-imidazolnylamino) quinoline compounds useful as alpha-2 adrenoceptor agonists
DE4438589A1 (de) 1994-10-28 1995-03-23 Reingard Dr Muenster Nasentherapeutikum
WO1996025163A1 (en) * 1995-02-14 1996-08-22 Board Of Supervisors Or Louisiana State Universityof Agricultural And Mechanical College Through Itsmedical Center Treatment of herpes simplex viruses
US5916900A (en) * 1995-06-29 1999-06-29 The Procter & Gamble Company 7-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists
DE19541919C2 (de) 1995-11-10 1997-11-20 Klosterfrau Mcm Vetrieb Gmbh Pharmazeutische Zubereitung zur Behandlung akuter Rhinitiden
EP0903151A1 (en) * 1997-09-22 1999-03-24 ASTA Medica Aktiengesellschaft Use of combinations comprising non-sedating antihistamines and alpha-adrenergic drugs for the topical treatment of rhinitis/conjunctivitis and cold, cold-like and/or flu symptoms
EP1326642A2 (en) 2000-09-29 2003-07-16 Board of Trustees operating Michigan State University Catecholamine pharmaceutical compositions and methods
DE60209511T2 (de) * 2001-09-18 2006-10-05 Nycomed Danmark Aps Zusammensetzungen zur behandlung des schnupfens, welche ipratropium und xylometazolin enthalten
RU2220739C1 (ru) * 2002-08-30 2004-01-10 Гапонюк Петр Яковлевич Интраназальное средство
DE10250944B9 (de) 2002-10-31 2004-09-16 Cell Center Cologne Gmbh Verwendung eines Stifts zur Applikation von Pflege- oder Wirkstoffen in die Nase
DE102004049008A1 (de) 2004-10-05 2006-04-06 Merck Patent Gmbh Neue Verwendung für α-Sympathomimetika mit 2-Imidazolinstruktur

Also Published As

Publication number Publication date
PL1802302T3 (pl) 2017-08-31
US20080108685A1 (en) 2008-05-08
RU2397764C2 (ru) 2010-08-27
EP1802302B1 (de) 2016-10-26
AU2005291603B2 (en) 2010-10-14
DK1802302T3 (en) 2017-02-06
KR20070059134A (ko) 2007-06-11
HUE031515T2 (en) 2017-07-28
MX2007004040A (es) 2007-05-24
PT1802302T (pt) 2017-02-07
WO2006037452A1 (de) 2006-04-13
EP1802302A1 (de) 2007-07-04
RU2007116719A (ru) 2008-11-20
AU2005291603A1 (en) 2006-04-13
JP2008515824A (ja) 2008-05-15
CY1118581T1 (el) 2017-07-12
JP5311825B2 (ja) 2013-10-09
CA2582984C (en) 2012-06-05
DE102004049008A1 (de) 2006-04-06
CN101022797A (zh) 2007-08-22
ES2612544T3 (es) 2017-05-17
ZA200703622B (en) 2008-08-27
LT1802302T (lt) 2017-02-10
CN101022797B (zh) 2010-12-15
CA2582984A1 (en) 2006-04-13

Similar Documents

Publication Publication Date Title
BRPI0411528A (pt) uso de isomalte como prebiótico
EA200802118A1 (ru) Обладающие ингибирующей активностью в отношении mnk1/mnk2 тиенопиримидины, предназначенные для применения в фармацевтических композициях
BRPI0917315B8 (pt) anticorpo monoclonal, seu uso e composição farmacêutica o compreendendo
UY28931A1 (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
BRPI0516483A (pt) preparo e uso de derivados de ácido bifenil-4-il-carbonilamino para o tratamento de obesidade
CR10099A (es) Inmunoglobulinas dirigidas contra nogo
BR122020006906B8 (pt) compostos e composições farmacêuticas antivirais
CL2007001847A1 (es) Composicion farmaceutica intramuscular o subcutanea que comprende tmc278 (rilpivirina); proceso para preparar la composicion; y uso para el tratamiento o prevencion de infeccion por vih.
BRPI0410503B8 (pt) composição tópica e uso da composição
CL2007001427A1 (es) Sal de maleato de 5-amino-3-(2&#39;,3&#39;-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d]pirimidin-2-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una infeccion po
ECSP12012211A (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
BRPI0618239A8 (pt) uso de flibanserina para o tratamento de distúrbios de desejo sexual pré-menopáusicos
PA8657201A1 (es) Compuestos de 3h-oxazolo y 3h-tiazolo [4, 5-d] pirimidin-2-ona 3, 5-disustituida y 3, 5, 7 - trisustituida y profarmacos de los mismos
ATE456369T1 (de) Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
MY186986A (en) Compositions and methods of use of phorbol esters
MY144318A (en) Methods of treating hiv infection.
CL2008000021A1 (es) Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer.
PA8575601A1 (es) Procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso
UA95103C2 (ru) Замещенные арилсульфонамиды в качестве противовирусных средств
ATE396697T1 (de) Zuckerlacton enthaltende zusammensetzung zur haarbehandlung
MA32841B1 (fr) Composés de cycloundeca depsipeptides et leur utilisation comme médicament
BRPI0518993A2 (pt) composto ou um sal, solvato ou Éster farmaceuticamente aceitÁvel do mesmo, composiÇço farmacÊutica, e, uso de um composto
BR0213684A (pt) Uso de antagonistas do receptor de endotelina para o tratamento de doenças tumorìgenas
WO2004026260A3 (en) Prophylactic and therapeutic hiv aptamers

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]